NasdaqHealth CareHealth Care ServicesS&P SmallCap 600
$13.77
+0.34 (+2.53%)
Close of Nov 06, 2026 · end-of-day data
LFST 8-K filings, explained
Every material Form 8-K Lifestance Health has filed with the SEC since November 06, 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
LifeStance reported third quarter 2026 revenue of $455.9 million, up 25%, and net income of $22.4 million, compared with $1.1 million a year earlier. The company raised its full-year 2026 guidance for revenue, Center Margin and Adjusted EBITDA, which points to stronger expected results for shareholders.
Q3 2026 revenue $455.9 million, up 25% from $363.8 million; net income $22.4 million versus $1.1 million
Adjusted EBITDA $68.4 million, up 70%; Center Margin $161.4 million, up 38%
Full-year 2026 revenue guidance raised to $1.741 billion to $1.761 billion; Adjusted EBITDA to $242 million to $250 million
Q4 2026 guidance: revenue $446 million to $466 million; Adjusted EBITDA $56 million to $64 million
LifeStance Health Group disclosed that director Teresa DeLuca, M.D., notified the board on October 14, 2026, of her resignation from the board and all of its committees, effective December 31, 2026. The company states the resignation is not the result of any disagreement with the company.
Teresa DeLuca, M.D., resigns from the board of directors and all committees.
Resignation notified to the board on October 14, 2026, effective December 31, 2026.
Company states the resignation does not result from any disagreement with Dr. DeLuca.
Filing does not name a replacement director or describe any financial effect.
LifeStance Health Group reported second-quarter 2026 revenue of $435.4 million, up 26%, and net income of $23.6 million, compared with a net loss of $3.8 million a year earlier. The company raised its full-year 2026 revenue, Center Margin and Adjusted EBITDA guidance and approved a new $100 million share repurchase program, which replaces its prior $100 million program from February 24, 2026.
Q2 2026 revenue was $435.4 million, up 26% from $345.3 million; net income was $23.6 million versus a net loss of $3.8 million in Q2 2025.
Adjusted EBITDA rose 94% to $66.0 million, or 15.2% of total revenue, compared with $34.0 million a year earlier.
Full-year 2026 revenue guidance was raised to $1.685 billion to $1.725 billion, and Adjusted EBITDA guidance is $215 million to $235 million.
The Board approved a $100 million share repurchase program on August 5, 2026, replacing the prior $100 million program approved February 24, 2026.
LifeStance Health Group said director Jeffrey Rhodes resigned from the board and all its committees effective immediately, and that the resignation was not due to any disagreement with the company. The board appointed Thurman Justice, Lori Goltermann and Safwan Shabab as directors to fill vacancies, a board change that is administrative in nature and carries no stated financial effect.
Jeffrey Rhodes resigned from the board and all committees effective immediately, notified July 2, 2026
Thurman Justice and Lori Goltermann appointed Class II directors, serving until the 2029 annual meeting
Safwan Shabab appointed Class III director under a June 9, 2021 stockholder agreement, serving until the 2027 meeting
Justice and Goltermann each received an initial award of 35,492 restricted stock units under the 2021 Equity Incentive Plan
LifeStance Health Group reported first-quarter 2026 revenue of $403.5 million, up 21%, and net income of $14.2 million, compared with $0.7 million a year earlier. The company raised its full-year 2026 revenue, Center Margin and Adjusted EBITDA guidance, which signals higher expected earnings for shareholders.
Q1 2026 revenue was $403.5 million, up 21% from $333.0 million; Adjusted EBITDA rose 48% to $51.1 million
Net income was $14.2 million, versus $0.7 million in Q1 2025; diluted EPS was $0.04 versus $0.00
Full-year 2026 revenue guidance raised to $1.640 billion to $1.680 billion, from $1.615 billion to $1.655 billion
Full-year 2026 Adjusted EBITDA guidance raised to $200 million to $220 million, from $185 million to $205 million
LifeStance Health Group promoted Lisa Miller, previously its Executive Vice President of Practice Operations, to Chief Operating Officer and Principal Operating Officer, effective March 10, 2026. The filing sets her base salary at $485,000 and a 2026 bonus target of 85% of base salary, plus an annual equity award with a target grant date value of about $1.5 million.
Lisa Miller, age 52, promoted to Chief Operating Officer and Principal Operating Officer on March 10, 2026
Annual base salary of $485,000 with a bonus target of 85% of base salary beginning in calendar 2026
Annual equity award of about $1.5 million target grant date value, split between time-based and performance-based restricted stock units
LifeStance reported fourth-quarter 2025 revenue of $382.2 million, up 17%, and net income of $11.7 million, compared with a net loss a year earlier, and issued 2026 guidance for revenue of $1.615 billion to $1.655 billion. The Board also approved a share repurchase program of up to $100 million and announced that Executive Chairman Kenneth Burdick will become non-executive Chairman effective March 16, 2026.
Q4 2025 revenue was $382.2 million, up 17%; full year revenue was $1,424.3 million, up 14%.
Q4 2025 net income was $11.7 million, versus a net loss of $7.1 million in Q4 2024; full year net income was $9.7 million.
2026 guidance: revenue of $1.615 billion to $1.655 billion and Adjusted EBITDA of $185 million to $205 million.
Board approved a repurchase program of up to $100 million of common stock; Kenneth Burdick moves to non-executive Chairman effective March 16, 2026.
LifeStance reported third-quarter 2025 results on November 6, 2025, with revenue of $363.8 million, up 16% from a year earlier, and net income of $1.1 million compared with a net loss of $6.0 million in the prior-year quarter. The company raised its full-year 2025 Adjusted EBITDA guidance to $146 million to $152 million and raised the midpoint of its Center Margin expectations, while reiterating its full-year revenue outlook of $1.41 billion to $1.43 billion.
Q3 2025 revenue of $363.8 million, up 16%; clinician base rose 11% to 7,996.
Net income of $1.1 million versus a $6.0 million net loss a year earlier; Adjusted EBITDA of $40.2 million, up 31%.
Full-year 2025 Adjusted EBITDA guidance raised to $146 million to $152 million; revenue guidance reiterated at $1.41 billion to $1.43 billion.
Fourth-quarter 2025 outlook: total revenue of $368 million to $388 million and Adjusted EBITDA of $37 million to $43 million.
LifeStance Health Group said director William Miller resigned from its board and all committees, effective immediately, and that the resignation was not due to any disagreement with the company. The board then appointed Sarah Personette as a director, granting her 74,766 restricted stock units that vest based on time and performance, subject to her continued board service.
William Miller notified the board of his resignation on August 19, 2025, effective immediately
The company stated the resignation was not the result of any disagreement with Mr. Miller
Sarah Personette was appointed a director on August 20, 2025
Ms. Personette received an initial award of 74,766 restricted stock units under the 2021 Equity Incentive Plan
LifeStance Health Group reported second-quarter 2025 revenue of $345.3 million, up 11% from a year earlier, and a net loss of $3.8 million, narrowed from $23.3 million. The company reiterated its full-year 2025 revenue outlook of $1.40 billion to $1.44 billion and raised its full-year Adjusted EBITDA and Center Margin expectations.
Q2 revenue was $345.3 million, up 11% from $312.3 million; visit volumes rose 12% to 2.2 million.
Net loss was $3.8 million versus $23.3 million a year earlier; Adjusted EBITDA rose 19% to $34.0 million.
Full-year 2025 Adjusted EBITDA raised to $140 million to $150 million; Center Margin raised to $441 million to $465 million.
Third-quarter 2025 revenue is expected at $345 million to $365 million.
LifeStance Health Group said Vaughn Paunovich will join as Chief Technology Officer effective June 9, 2025, succeeding Chief Digital Officer Pablo Pantaleoni, who is leaving on July 1, 2025. The filing also describes a separation agreement for Pantaleoni with severance-type payments and equity vesting, subject to a release and continued compliance with restrictive covenants.
Vaughn Paunovich becomes Chief Technology Officer effective June 9, 2025; he previously served as EVP, Enterprise Platforms at Amwell.
Pablo Pantaleoni's departure takes effect July 1, 2025 (the Transition Date).
Pantaleoni will receive an amount equal to his annual base salary in two installments, 12 months of COBRA premiums, and vesting of certain restricted stock units after January 1, 2026.
CEO Dave Bourdon said Paunovich will lead the company's end-to-end technology strategy.
LifeStance Health Group reported first-quarter 2025 revenue of $333.0 million, up 11% from $300.4 million a year earlier, and net income of $0.7 million compared with a net loss of $21.1 million in the prior-year quarter. The company reaffirmed its full-year 2025 guidance for revenue, Center Margin and Adjusted EBITDA, and gave second-quarter revenue guidance of $332 million to $352 million.
Q1 2025 revenue of $333.0 million, up 11%; Adjusted EBITDA of $34.6 million, up 25%
Net income of $0.7 million versus a net loss of $21.1 million in Q1 2024
Net cash used in operations was $3.1 million in Q1; cash ended the quarter at $134.3 million
Full-year 2025 guidance reiterated: revenue $1.40 billion to $1.44 billion; Adjusted EBITDA $130 million to $150 million
LifeStance's board promoted David Bourdon, the company's CFO since 2022, to Chief Executive Officer effective March 3, 2025, succeeding Kenneth Burdick, who is retiring as CEO and will serve as Executive Chairman. Ryan McGroarty was named Chief Financial Officer and Treasurer effective March 17, 2025, to succeed Bourdon in that role. The filing does not include financial results.
Bourdon becomes CEO effective March 3, 2025, with a $700,000 annual base salary and a target bonus of 100% of base salary.
Burdick, CEO since 2022, retires as CEO and becomes Executive Chairman with a $200,000 annual base salary.
McGroarty becomes CFO effective March 17, 2025, with a $550,000 base salary, a target bonus of 85% of base salary, and a $570,000 one-time signing bonus.
McGroarty's one-time equity award has an aggregate target grant date value of approximately $5,000,000.
LifeStance Health Group reported fourth-quarter and full-year 2024 results on February 27, 2025. Revenue grew 19% for the full year to $1.25 billion, and the full-year net loss narrowed to $57.4 million from $186.3 million in 2023. The company also expects 2025 revenue of $1.40 billion to $1.44 billion and Adjusted EBITDA of $130 million to $150 million.
Q4 2024 revenue was $325.5 million, up 16%; full-year revenue was $1.25 billion, up 19%.
Q4 2024 net loss was $7.1 million versus $45.0 million a year earlier; full-year net loss was $57.4 million versus $186.3 million.
Full-year 2024 Adjusted EBITDA was $119.7 million, up 103%; Free Cash Flow was $85.7 million.
2025 guidance: revenue of $1.40 billion to $1.44 billion, Center Margin of $440 million to $464 million, Adjusted EBITDA of $130 million to $150 million; Q1 2025 revenue of $320 million to $340 million.
LifeStance's subsidiary entered a new credit agreement with Capital One as administrative agent, funding a $290.0 million senior secured term loan on December 19, 2024 and establishing a $100.0 million revolving facility. Proceeds were used to repay and terminate the existing credit agreement dated May 4, 2022, and both facilities mature on the fifth anniversary of the closing date.
Term loan facility of $290.0 million, funded on December 19, 2024, with interest at adjusted term SOFR (0.00% floor) plus 3.00% or a base rate plus 2.00%
Revolving facility commitments of up to $100.0 million, with a 0.45% per annum undrawn commitment fee subject to leverage-based stepdowns
Proceeds used to repay all outstanding loans under the May 4, 2022 credit agreement, which was terminated
Obligations are guaranteed by Holdings and certain subsidiaries and secured by substantially all assets of the Borrower, Holdings and subsidiary guarantors
LifeStance Health Group reported third-quarter 2024 revenue of $312.7 million, up 19% from a year earlier, and a net loss of $6.0 million, down from $61.6 million. The company raised its full-year 2024 revenue, Center Margin and Adjusted EBITDA expectations, which gives shareholders a higher outlook than before the report.
Q3 2024 revenue was $312.7 million, up 19%; Adjusted EBITDA was $30.7 million, up 110%
Net loss narrowed to $6.0 million from $61.6 million in Q3 2023
Full-year 2024 revenue guidance raised to $1.228 billion to $1.248 billion; Adjusted EBITDA guidance raised to $105 million to $115 million
Company continues to expect positive Free Cash Flow for full-year 2024
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Lifestance Health filing is on SEC EDGAR ↗. 8-K briefs of other companies →